By Colin Kellaher Shares of BioVie Inc. rose sharply in premarket trading Tuesday after the clinical-stage biopharmaceutical company reported positive results from a pair of Phase 2 studies assessing the
Roche Holding AG said Monday that Phase 3 Graduate studies of gantenerumab, for treatment of early Alzheimer’s disease, failed to meet its primary endpoints. The Swiss pharma company ROG, -3.72% Read more Biogen Inc. BIIB, -1.93% and Eisai Co. Ltd. 4523, +3.57% are getting closer to a possible approval of their new treatment for Alzheimer’s disease, with plans to submit the drug Read more This article is reprinted by permission from NerdWallet. While inflation is pushing up prices for almost everything else, Medicare is about to be less expensive. Medicare Part B premiums will Read more An experimental Alzheimer’s disease treatment developed by Eisai and Biogen that appears to slow cognitive decline sent shares in both companies soaring, but some analysts are tempering their expectations until Read more Next stop regulatory approval. That was the view of analysts at Mizuho Securities, who late Tuesday lifted shares of Biogen Inc. BIIB, +1.04% to buy from neutral after the pharmaceutical Read more Eisai Co. shares were indicated sharply higher Wednesday morning after the Japanese drug maker and Biogen Inc. said their experimental Alzheimer’s disease drug significantly slowed progression of the disease in Read more Eisai Co. 4523, +0.89% and Biogen Inc. BIIB, +1.04% said their experimental Alzheimer’s disease drug significantly slowed progression of the memory-robbing disease in a large study, bolstering the drug’s prospects for approval. The pharmaceutical companies Read more Could cold sores plus shingles lead to Alzheimer’s? New research from Tufts and Oxford universities adds to the growing evidence that they might — and how. And the implications are Read more
Roche says Phase 3 studies for Alzheimer’s drug failed to meet primary endpoints
Biogen and Eisai make plans to take another Alzheimer’s drug to the FDA
Here’s one thing that will cost less next year—what it means for Medicare beneficiaries
Getting Medicare to cover Eisai and Biogen’s promising new Alzheimer’s therapy is ‘another bridge to cross’
Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer’s drug success
Eisai shares indicated sharply higher after trial of experimental drug slows Alzheimer’s progression
Alzheimer’s drug from Eisai, Biogen shows promise in large trial
Cold sores and shingles may be linked to Alzheimer’s, new research indicates